Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Xintela’s strategy for 2023

2022 was an eventful and successful year for Xintela. The company entered into clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers and thus has two ongoing clinical phase I/IIa studies with XSTEM. In addition, further development of EQSTEM for the treatment of joint diseases in horses is planned. In parallel with the stem cell projects, a phase 0 study is being prepared in the subsidiary Targinta. Xintela’s CEO Evy Lundgren-Åkerlund tells us more about the plans for 2023 in an interview with BioStock.Read the full article at biostock.se:

CGit takes a new order with a new customer, value SEK 1.5 million

Mölndal                                                                               2023-02-17 CGit takes a new order with a new customer, value SEK 1.5 million. CGit takes a new order in communication and security. A customer active in the automotive industry signs an agreement regarding delivery in communication and security to ensure capacity and meet the company's needs for the next generation communication and security platform. CGit thanks you for the trust, says Mattias Bergkvist, CEO of CGit. CGit continues to build its knowledge base in AI/Deep Learning. // For

Latour publishes updated base prospectus for the company's existing MTN-Programme

Investment AB Latour (publ) (“Latour”) has prepared an updated base prospectus for the company's existing MTN-Programme that today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and been published on Latour’s web page. Latour established a programme for issuance of bonds, so called Medium Term Note programme, on February 19, 2018. MTN may be issued in SEK or EUR with varying tenors, but at least one (1) year. Nominal value per MTN may not be less than EUR 100,000 (or its equivalent in SEK). The general terms and conditions of the MTN-Programme,

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 46 - 17 FEBRUARY 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 40/23 and 42/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Cell Impact reports fourth quarter results: Solid year-end results 2022

Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the fourth quarter.The higher production activity trend Cell Impact saw at the end of the third quarter also continued into the fourth quarter. During the quarter, we received a number of small, but important, orders for test tools that we expect will become full-scale tooling projects and prototype series during 2023. In industrial terms, Cell Impact continued to develop through further enhancing production equipment and strong growth in flow plate production. Even if new orders for important tooling projects

MapsPeople – Announces a directed issue of new shares in a private placement and entering into a new loan facility raising gross proceeds of DKK 20 million

MapsPeople A/S | Inside Information  Company Announcement No. 2 - 2023 Aalborg, February 17, 2023· MapsPeople commenced a directed share offering to Kapitalforeningen BankInvest Select Small Cap Danske Aktier KL and Vækstfonden · MapsPeople enters into a new loan facility agreement with Vækstfonden · Today, 17 February 2023, MapsPeople’s board of directors has exercised an authorization to increase the share capital by issuing 2,444,488 new shares. · The new shares will be issued at a subscription price of DKK 4.09 per new share. · The aggregate gross proceeds from the

LDA partially converts its convertible loan

Endomines Finland Plc – Stock Exchange Release, 17.2.2023, at 11.00 EET.   As communicated by Endomines on January 4th, 2023, Endomines issued a convertible loan to LDA Capital Limited (LDA) for a total amount of EUR 1,000,000 based on LDA’s investor call request. LDA has notified Endomines that LDA wishes to convert part of this loan, total EUR 200,000, into new Endomines shares. After this conversion, the remaining LDA convertible loan totals EUR 400,000. Under the terms of the convertible loan agreement between the parties, the conversion price corresponds to 85 percent of the

YEAR-END REPORT 2022

2022 FINANCIAL YEAR · Rental revenue increased 19% to SEK 3,696 M (SEK 3,100 M in the year-earlier period). · Profit from property management increased 19% to SEK 3,339 M (2,805). · Profit from property management per Class A and B share after dilution rose 21% to SEK 9.70 (7.99). · Property revaluation had an impact on profit of SEK 2,233 M (6,340). · Revaluation of financial instruments had an impact on profit of SEK -2,025 M (1,966). · Profit after tax for the year was SEK 2,718 M (9,807). · Cash flow from operating activities before changes in working capital rose

Etteplan Oyj's Corporate governance statement, Statement of non-financial information and Remuneration report for 2022 published

ETTEPLAN OYJ, Stock Exchange Release, February 17, 2023, at 11.00 a.m. Etteplan Oyj's Corporate governance statement, Statement of non-financial information and Remuneration report for 2022 published Etteplan Oyj’s Corporate governance statement and Remuneration report for 2022 have been published. Etteplan has also published its Statement of non-financial information for 2022 which includes EU taxonomy report. The statements and report have been published in PDF format as attachments to this stock exchange release and are also available on the Company’s website www.etteplan.com (

Loomis AB’s holding of own shares exceeds five percent

As of February 16, 2023, Loomis AB held 3,777,782 own shares, corresponding to 5.02 percent of the votes and capital in the company. The total number of shares in Loomis AB, including the company's own shares, amounts to 75,279,829.   The Board of Directors of Loomis AB resolved, and communicated, on February 1, 2023, to continue to repurchase of own shares during the first quarter 2023 by virtue of the authorization granted by the annual general meeting 2022. The repurchase of shares commenced on February 3, 2023.   For information about transactions in the repurchase program,

First day of trading in Upgrade Invest Nordic

Today is the first day of trading in the investment company Upgrade Invest Nordic. The company is working towards the vision of becoming a partner to growth companies intending to go public.Upgrade is an investment company that invests primarily in growth companies that intend to go public within two years. The investment strategy is not limited to any particular sector or industry, and investment decisions can be made for the short or long term. Upgrade keeps abreast of investment opportunities, using both the Board's existing business relationships and publicly available market

Risk Intelligence A/S changes revenue recognition to full periodisation to improve investor transparency and comparison with peers

Risk Intelligence A/S (“Risk Intelligence” or the “Company") announces today that the company from and including the financial year of 2022 has changed its financial reporting standards to full revenue periodisation to comply with market standards for SaaS companies.The Board of Directors of Risk Intelligence has had an ongoing discussion about changing the revenue recognition from date of invoicing to full periodisation for subscription-based licenses, which constitute about 90% of total revenue. The Board of Directors has therefore decided to follow the requirement from Deloitte to change

CS MEDICA A/S: Release of 2022/2023 Q1 report, for the period October – December 2022, including an invitation to a live-streamed conference call on 22nd February, at 10 AM CET.

CS MEDICA (”CS MEDICA” or the ”Company”) hereby releases its Q1 report for the period October– December 2022. Highlights of the period will be presented at a live-streamed conference call on Wednesday the 22nd of February at 10 AM CET. The Q1 report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.Growing through transformation and in turbulent timesWe operate in new territories within healthcare treatments, and with the cannabis industry's early stages of regulations and transparency, we witness

Altor acquires majority of VTU and partners with management

Stockholm/Vienna, 17/02/2023 - Altor Funds (“Altor”) have signed an agreement to acquire a majority in VTU Group GmbH (“VTU”), a leading Life Sciences and Green Transition process engineering company, from funds advised by DPE Deutsche Private Equity Management III GmbH. VTU’s management will reinvest in the Company.  Altor will support VTU’s strategy to become a European leader in high value-added process engineering services for Life Sciences industries and a sector specialist in Green Transition process engineering.  The closing is subject to regulatory approval.Founded in 1990 in Graz,

New multi-modality Hybrid OR installation to support better patient outcomes in Italy

Recently, two new multi-modality hybrid operating rooms (Hybrid ORs) opened up at Azienda Ospedale at the University of Padua in Italy, following a successful partnership between the hospital, Getinge and Siemens Healthineers. The state-of-the-art installation will support the hospital staff in their ambition to achieve better patient outcomes. Responding to the demand for surgeries that require multiple surgical teams and technologies, an installation of two new multi-modality Hybrid ORs at the Azienda Ospedale at the University of Padua is one of the so far most advanced efforts

Invitation to Etteplan Oyj’s Annual General Meeting of Shareholders

ETTEPLAN OYJ, Stock Exchange Release, February 17, 2023 at 10.00 a.m. INVITATION TO ETTEPLAN OYJ’S ANNUAL GENERAL MEETING OF SHAREHOLDERS The shareholders of Etteplan Oyj (“Company”) are invited to the Annual General Meeting of Shareholders. The Meeting will be held on Wednesday April 5, 2023 starting at 9:00 a.m. at Leonardo auditorium, Innopoli 1 at the address Tekniikantie 12, 02150 Espoo, Finland. The reception of the persons who have registered for the Meeting will commence at 8:30 a.m. Shareholders can attend the meeting at the meeting venue. A. MATTERS ON THE AGENDA OF THE

Crunchfish Q4 webinar

Crunchfish AB ("Crunchfish") Q4 webinar is now available, where Crunchfish CEO Joachim Samuelsson is interviewed by analyst Joen Sundmark from Västra Hamnen Corporate Finance. Accompanying the release of the company's year-end report, Crunchfish are launching Crunchfish iQ, an interactive view of the year-end report.   The webinar about Crunchfish year-end report for Q4 2022 is now available via the following link: Webinar Q4    Crunchfish year-end report for Q4 2022 is available via the following link: Crunchfish Q4 (

Finnair's 2022 Annual Report has been published

Finnair Plc           Annual financial report           17 February 2023 at 10.00 a.m. EET Finnair Plc’s Report of the Board of Directors and Financial Statements 2022 were published today on 17 February 2023. The Report of the Board of Directors includes non-financial reporting.  Finnair publishes separately a Financial Information 2022 report, inclusive of Finnair Plc’s Report of the Board of Directors and Financial Statements, also in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format of the report is Extensible Hypertext Markup Language

Viaplay to produce original Polish dramedy ‘Stroke’

· Dramatic comedy is Viaplay’s second scripted commission in Poland · ‘Stroke’ created by acclaimed playwright and screenwriter Paweł Demirski and stars Jacek Poniedziałek (‘A Heart of Love’; ‘The Reverse’) · Eight-part series to premiere in 2023 Viaplay has commissioned the eight-part Polish dramatic comedy ‘Stroke’, starring Jacek Poniedziałek (the major films ‘A Heart of Love’ and ‘The Reverse’) as a Warsaw bon vivant and popular TV host whose life is suddenly turned upside down. Created by acclaimed playwright and screenwriter Paweł Demirski (‘Artysci’), ‘Stroke’ will premiere

MAJOR SHAREHOLDER ANNOUNCEMENT

ANNOUNCEMENT NO. 45 - 17 FEBRUARY 2023 Pursuant to section 31 of the Danish Capital Markets Act it is hereby announced that Dampskibsselskabet NORDEN A/S holds a total of 3,703,183 treasury shares in Dampskibsselskabet NORDEN A/S, corresponding to 10.01% of the entire share capital and voting rights.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release February 17, 2023 at 9:45 a.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on February 16, 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total holding in Nokian Tyres shares and voting rights owned by the funds and accounts managed by JPMorgan Chase & Co. fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on February 15, 2023. Total positions of person(s) subject to the notification

HC Andersen Capital Events 17/02: Mød topledelsen i Bavarian Nordic

HC Andersen Capital afholder i dag et spændende event, hvor du kan møde og stille spørgsmål direkte til topledelsen. Det er frit for alle og gratis at deltage.Bavarian Nordic - Manifesterer sig som en førende aktør indenfor rejsevacciner, 2023 guidanceVaccineselskabet Bavarian Nordic var den 15. februar 2023 ude med nyheden om køb af rejsevacciner samt et fase 3 udviklingsprojekt med tilhørende R&D- og produktionsfaciliteter fra Emergent Biosolutions samt offentliggørelse af 2023 guidance.     Mød Bavarian Nordics EVP & CFO Henrik Juuel, der vil give et indblik i ovenstående

Year-End Report 2022

ChromoGenics received order from Vasakronan and enters into cooperation in GermanyQ4 2022 · In Q4 2022, ChromoGenics’ net sales amounted to SEK 3.5 (13.7) million, a decrease of SEK 10.2 million compared to the corresponding quarter in 2021. A weakened market situation and challenges in the production had a negative impact on net sales for the quarter. · ChromoGenics’ operating loss for the fourth quarter of the year amounted to SEK -11.6(-14.7) million, which is an improvement of SEK 3.2 million compared to the corresponding period in 2021. The company’s operating result benefits

There are no items matching the current filter
There are no more items matching the current filter
Back to top